

# Cedric Dos Santos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10724859/publications.pdf>

Version: 2024-02-01

16  
papers

1,093  
citations

840776

11  
h-index

940533

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

2090  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 153-162.	1.2	16
2	A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2020, 112, 223-233.	1.6	8
3	Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. <i>Cancer Science</i> , 2020, 111, 1314-1323.	3.9	19
4	Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells. <i>Haematologica</i> , 2018, 103, 959-971.	3.5	36
5	Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. <i>Oncogene</i> , 2018, 37, 5269-5280.	5.9	65
6	Treatment of Acute Myeloid Leukemia in Elderly Patients – A Therapeutic Dilemma. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 581-587.	2.5	10
7	Signal Transduction Inhibitors as Promising Anticancer Agents. <i>BioMed Research International</i> , 2015, 2015, 1-2.	1.9	2
8	Combination of Dasatinib with Conventional Chemotherapy Is Associated with a High Response Rate in High Risk Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 3743-3743.	1.4	3
9	SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells. <i>Cell Stem Cell</i> , 2014, 15, 431-446.	11.1	187
10	The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. <i>Blood</i> , 2013, 122, 1900-1913.	1.4	86
11	In Vivo Targeting Of Acute Myeloid Leukemia Using CpG-Stat3 siRNA Results In T Cell-Dependent Tumor Eradication. <i>Blood</i> , 2013, 122, 4212-4212.	1.4	1
12	A functional link between Polo-like kinase 1 and the mammalian Target-Of-Rapamycin pathway?. <i>Cell Cycle</i> , 2010, 9, 1690-1696.	2.6	26
13	Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. <i>Blood</i> , 2009, 114, 659-662.	1.4	127
14	A critical role for Lyn in acute myeloid leukemia. <i>Blood</i> , 2008, 111, 2269-2279.	1.4	137
15	Antileukemic activity of rapamycin in acute myeloid leukemia. <i>Blood</i> , 2005, 105, 2527-2534.	1.4	280
16	mTOR, A New Therapeutic Target in Acute Myeloid Leukemia. <i>Cell Cycle</i> , 2005, 4, 1540-1549.	2.6	90